Seonix Bio has announced the U.S. launch of SightScore, a clinical polygenic risk-testing service for primary open-angle glaucoma. SightScore uses a saliva test to identify individuals at high risk for glaucoma, enabling earlier diagnosis and intervention as well as more personalized treatment. The test can also identify low-risk individuals who may benefit from less frequent monitoring, the company said in a press release.

SightScore examines millions of variants in the patient’s genome to estimate their genetic risk of developing glaucoma in the future. It can also assess the risk of progression in those who have already been diagnosed with glaucoma, helping clinicians to prioritize and manage patients at highest risk.

“In the past, clinical genetic risk assessment for glaucoma has targeted a single gene or tens of genetic variants. As the first truly polygenic clinical genetic risk score for glaucoma on the market, using 7 million genetic variants, SightScore represents a major step forward in how we diagnose and manage this disease,” said Nick Haan, CEO of Seonix Bio, in the press release.

“SightScore is a game changer in the way we will assess and manage patients at risk for glaucoma. It is an invaluable tool for identifying individuals who may not show obvious signs of the disease yet and are at higher genetic risk,” Dr. Inder Paul Singh, president of The Eye Centers of Racine & Kenosha, Ltd. in Wisconsin, said in the press release. “By incorporating SightScore into our practice, we can more effectively prioritize patients for early screening, personalize their care, and ensure we’re detecting glaucoma in its earliest, most treatable stages.”

According to Seonix Bio, SightScore can be referred online by an appropriate health professional and involves a simple saliva collection process, followed by genetic analysis and receipt of a clinical report.